Pharmacokinetic profile of zafirlukast

Clinical Pharmacokinetics

Volumn 41, Issue 2, 2002, Pages 105-114

  Dekhuijzen, P N R ^a   Koopmans, P P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; CORTICOSTEROID; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; ERYTHROMYCIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; TERFENADINE; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ALCOHOL LIVER CIRRHOSIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CHURG STRAUSS SYNDROME; CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; HEADACHE; HUMAN; KIDNEY FAILURE; LACTATION; LIVER METABOLISM; NONHUMAN; PHARYNGITIS; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW;

EID: 0036201968     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241020-00003     Document Type: Review

References (56)

1. Leukotrienes as a target in asthma therapy
2. Zafirlukast: A review of its pharmacology and therapeutic potential in the management of asthma
3. The role and contribution of leukotrienes in asthma
4. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy
5. Comparison of zafirlukast (Accolate) absorption after oral and colonic administration in humans
6. Metabolism and excretion of zafirlukast in dogs, rats, and mice
7. The preclinical pharmacology of ICI 204,219: A peptide leukotriene antagonist
8. Pharmacology of leukotriene receptor antagonists
9. An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways
10. Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICI 204,219 (Accolate)
11. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma
12. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast
13. Asthma drug linked with Churg-Strauss syndrome
14. Steroids and Churg-Strauss syndrome
15. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast
16. Churg-Strauss syndrome associated with zafirlukast
17. Churg-Strauss syndrome associated with zafirlukast
18. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment
19. Leukotriene modifiers and Churg-Strauss syndrome: Adverse effect or response to corticosteroid withdrawal?
20. Pulmonary eosinophilia associated with montelukast
21. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma
22. Leukotriene-receptor antagonists
23. Treatment of asthma with drugs modifying the leukotriene pathway
24. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction
25. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI 204,219
26. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy
27. The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: The possible role of leukotrienes in exercise-induced refractoriness
28. Role of leukotrienes in exercise-induced asthma: Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist
29. Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma
30. Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction
31. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
32. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma
33. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics
34. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
35. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge
36. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge
37. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
38. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial
39. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction
40. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma
41. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
42. Two first-line therapies in the treatment of mild asthma: Use of peak flow variability as a predictor of effectiveness
43. Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn beta-2-agonists
44. Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma
45. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: An integrated analysis of zafirlukast trials
46. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
47. Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection
48. Zafirlukast is a substrate for CYP2C9 and an inhibitor of CYP2C9 and CYP3A in vitro
49. A drug interaction between zafirlukast and theophylline
50. Effect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men
51. Effect of zafirlukast on prothrombin time and area under the curve of warfarin
52. The pharmacokinetics of zafirlukast and terfenadine after coadministration in healthy men
53. Effect of zafirlukast on QTc and area under the curve of terfenadine in healthy men
54. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers